Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Adults
NCT ID: NCT06334393
Last Updated: 2025-08-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE1
150 participants
INTERVENTIONAL
2024-03-25
2026-04-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The primary objective of this trial is to assess the safety and tolerability of the vaccine candidate up to 7 days after each vaccination; and to assess the immune response induced by the vaccine candidate 28 days after the second vaccination. Additionally, safety and immune response of the vaccine candidate will be monitored throughout the trial.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety, Tolerability, and Immunogenicity of mRNA-1325 in Healthy Adult Subjects
NCT03014089
A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Ad26.ZIKV.001 in Healthy Adult Volunteers
NCT03356561
Chikungunya Virus Vaccine Trial in Healthy Adults
NCT01489358
Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults
NCT03483961
Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine (VLA1553)
NCT04838444
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This is a phase 1 trial, consisting of an initial open-label sentinel run-in (n=25) phase and a randomized, double-blind, dose-finding trial (n=125) in flavivirus naïve adults aged 18 to 49 years. In total approximately 150 participants will be vaccinated in this trial.
The trial will investigate three antigen dose levels (low, medium and high) of VLA1601. In addition, CpG 1018® or 3M-052-AF/AP 60-702 are investigated as add-on adjuvants in the low dose group (bedside mixing). Each dose is formulated with alum (aluminum hydroxide) adjuvant.
In each of the five treatment arms 30 participants (each with 5 sentinel/run-in and 25 randomized participants) will be vaccinated. Each participant will receive 2 vaccinations, one on Day 1 and one on Day 29, which will be administered intramuscularly (i.m.) in the deltoid muscle (non-dominant arm). The screening period can last up to 21 days.
The trial began with the vaccination of 25 sentinel participants (5 participants in each of the 5 treatment arms) in a sequential open-label, staggered dose-escalation manner.
Up to approximately 125 participants will be randomized 1:1:1:1:1, stratified by trial site to 5 treatment arms. The injection volume in each treatment arm will be 0.45 mL at each of the 2 vaccinations.
The primary objective of this trial is to assess the safety and tolerability of the vaccine candidate up to 7 days after each vaccination; and to assess the immune response induced by the vaccine candidate 28 days after the second vaccination.
Following a sponsor review of available safety and immunogenicity data up to 6 months after the second vaccination, all sentinels and randomized participants from most favorable treatment arm(s) will be selected for an on-site visit at Day 395 for long-term safety and immunogenicity assessment. All other treatment arms will be followed only by phone-call for the Day 395 assessment of long-term safety.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
VLA1601 Low dose
VLA1601
0.45mL (milliliter), Day 1 and 29
VLA1601 Low dose + CpG 1018®
VLA1601
0.45mL (milliliter), Day 1 and 29
CpG 1018®
CpG 1018® will be investigated in combination with VLA1601 Low dose
VLA1601 Low dose + 3M-052-AF
VLA1601
0.45mL (milliliter), Day 1 and 29
3M-052-AF
3M-052-AF will be investigated in combination with VLA1601 Low dose
VLA1601 Medium dose
VLA1601
0.45mL (milliliter), Day 1 and 29
VLA1601 High dose
VLA1601
0.45mL (milliliter), Day 1 and 29
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
VLA1601
0.45mL (milliliter), Day 1 and 29
CpG 1018®
CpG 1018® will be investigated in combination with VLA1601 Low dose
3M-052-AF
3M-052-AF will be investigated in combination with VLA1601 Low dose
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI of ≥18.5 and \<30 kg/m2
* generally healthy as determined by the investigator's clinical judgement based on medical history, physical examination, and screening laboratory tests.
* If trial participant is of childbearing potential: negative pregnancy test; employ adequate birth control measures up to Day 208.
* Male participant agrees to employ adequate birth control measures up to 90 days after last vaccination.
Exclusion Criteria
* has a known history of the following flavivirus infection: Zika Virus (ZIKV), Japanese Encephalitis Virus (JEV), Dengue Virus (DENV), Yellow Fever Virus (YFV), West-Nile Virus (WNV), or Tick-Borne Encephalitis Virus (TBEV).
* received or has plans to receive a licensed or investigational flavivirus vaccine during the course of the trial.
* travelled within 4 weeks prior to trial enrollment or has plans to travel to areas (including within the US) with Zika virus (ZIKV), Japanese Encephalitis Virus (JEV), Dengue Virus (DENV) or Yellow Fever Virus (YFV) active transmission/circulation during the course of the trial .
* received active or passive immunization within 4 weeks prior or planned to get such vaccination after any trial-vaccination.
* presents with clinically significant abnormal laboratory values, as determined by the investigator.
* tests positive for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV).
* has history of significant cardiovascular, respiratory (including asthma), metabolic, neurological (including Guillain-Barre syndrome \[GBS\]), psychiatric, hepatic, rheumatic, autoimmune, hematological, gastrointestinal, or renal disorder.
* with known or suspected defect of the immune system that would prevent an immune response to the vaccine.
* received immuno-suppressive therapy within 4 weeks prior to first vaccination. Radiation therapy or immunosuppressive cytotoxic drugs/ monoclonal antibodies in the previous 3 years.
* with a history of severe hypersensitivity reactions or anaphylaxis.
* with a history of any vaccine related contraindicating event .
* with acute febrile infections within two weeks prior to vaccination in this trial.
* donated blood within 4 weeks or received blood-derived products (e.g. plasma) within 12 weeks prior to vaccination in this trial or plans to donate blood or use blood products during the course of the trial.
* has a rash, dermatological condition or tattoos that would, in the opinion of the investigator, interfere with injection site reaction rating.
* presents with clinical conditions representing a contraindication to intramuscular vaccination and blood draws.
* is currently enrolled (ICF signed) or has participated in another clinical trial involving an investigational medicinal product (IMP) or device within 4 weeks prior to trial enrollment or is scheduled to participate in another clinical trial involving an IMP or investigational device during the course of this trial.
* has a known or suspected problem with alcohol or drug abuse
18 Years
49 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Valneva Austria GmbH
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Flourish Research
Chicago, Illinois, United States
Velocity Clinical Research
Sioux City, Iowa, United States
Velocity Clinical Research
Lincoln, Nebraska, United States
Velocity Clinical Research
Omaha, Nebraska, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VLA1601-102
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.